Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Address correspondence to: Arturo Casadevall, Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, 615 N. Wolfe Street, Room E5132, Baltimore, Maryland 21205, USA. Phone: 410.955.3457; Email: email@example.com.
Published January 6, 2020 - More info
Climate change will bring major changes to the epidemiology of infectious diseases through changes in microbial and vector geographic range. Human defenses against microbial diseases rely on advanced immunity that includes innate and adaptive arms and endothermy, which creates a thermal restriction zone for many microbes. Given that microbes can adapt to higher temperatures, there is concern that global warming will select for microbes with higher heat tolerance that can defeat our endothermy defenses and bring new infectious disease.
Almost three decades ago, experts began to sound the alarm that climate change could be associated with changes to the epidemiology of infectious diseases (1, 2). Since then a large body of literature has accumulated on this subject focused primarily on how climate will affect locations of pathogenic microbes and vectors of infectious diseases. In this Viewpoint, I focus on another threat: the strong possibility that new, previously unknown infectious diseases will emerge from warmer climates as microbes adapt to higher global temperatures that can defeat our endothermy thermal barrier.
The field of infectious diseases has the unenviable distinction of being the only subdiscipline of medicine that routinely has to deal with new diseases and where therapies lose their potency and value from drug resistance. New infectious diseases caused by pathogenic microbes not previously known to medicine emerge from acquisition from another species (e.g., species jump), as occurred with HIV, and from increased susceptibility in humans who become immunosuppressed, who are often the source of so-called opportunistic pathogens. The latter are rare and are usually the topic of case reports, although epidemics can occur, as exemplified by the outbreak of Exserohilum rostratum meningitis following the use of contaminated steroids in 2012 (3). Even though new infectious diseases are relatively frequent, with several reported each year, they involve a miniscule proportion of the microbial flora in the biosphere, which is a testament to remarkably powerful defense mechanisms in humans and mammals.
The human organism is protected from infectious diseases by an advanced immune system that includes innate and adaptive arms and physical defenses. Although physical defenses such as skin are well known to physicians, the role of temperature is often unappreciated. Mammals are remarkable among animals in their endothermy and homeothermy, which maintains an elevated body temperature through life. Infectious diseases are acquired from other hosts (e.g., influenza virus) or directly from the environment, usually by inhalation (e.g., cryptococcosis and histoplasmosis). Microbes acquired from other humans are already adapted to mammalian temperatures, and these are not inhibited by endothermy. However, for many microbes, especially those in the environment that are adapted to cooler ambient temperatures, mammalian endothermy creates a thermal inhibitory zone. For example, about 95% of fungal species are inhibited by human core temperatures (4), which probably accounts for the paucity of fungal diseases in mammals relative to their high frequency in ectothermic species such as plants and insects.
The synergistic efficacy of the twin pillars of advanced immunity and endothermy in protection against fungi is evident from two situations (Figure 1). Events that damage the immune pillar, such as HIV infection and immunosuppressive therapies, are associated with a high prevalence of infectious diseases that are very rare in immunologically intact hosts. As to the endothermy pillar, there are no good examples of fungal diseases associated with hypothermia because humans are not capable of surviving prolonged periods of colder body temperatures. However, evidence for the importance of the endothermy pillar comes from hibernating animals such as bats, which are susceptible to the fungal disease white-nose syndrome during the winter (5). Hence, interference with either pillar makes mammalian hosts susceptible to infectious diseases.
The remarkable resistance of humans (and mammals) to fungal diseases rests on the two pillars of advanced immunity and endothermy (i.e., the state of being warm-blooded). Immune suppression or climate change with microbial adaptation to survive at higher temperatures can undermine these pillars and make the host vulnerable to fungal disease.
Regarding climate change, there is a specific concern about new diseases from the fungal kingdom (6). The endothermy pillar is robust in humans, but it can be defeated if the fungi adapt to higher temperatures. Although most fungal species cannot tolerate mammalian temperatures (4), some species can be trained to survive higher temperatures by gradual exposure to warmer temperatures. Hence, we have proposed that global warming will lead many fungal species to adapt to higher temperatures, and some with pathogenic potential for humans will break through the thermal defensive barrier provided by endothermy (6). The nearly simultaneous emergence of Candida auris on three continents (7), an event proposed to result from global warming (8), has raised the specter that increased warmth by itself will trigger adaptations on certain microbes to make them pathogenic for humans. Fungi that are pathogenic for insects can be experimentally adapted to replicate at mammalian temperatures through cycles of progressive warming, demonstrating that fungi are able to adapt rapidly to higher temperatures (9).
The concern is that there are a large number of fungal species that are pathogenic to plants and ectothermic animals, which means that they have the virulence tools to defeat immunity in these hosts, and if they adapt to higher temperatures, that could pose a new threat to humans. The same concern raised with the fungi applies to other microbes. Viruses are completely dependent on their hosts for replication and survival. As hosts adapt to higher temperatures, their associated viruses must follow suit to survive. Viruses associated with ectothermic animals that currently pose no threat to humans could jump to mammals if they acquire the capacity for replication at higher temperatures. Similar arguments apply to bacteria and parasites. Hence, the conceptual threat originally identified with fungi, and exemplified by C. auris as the canary in the coal mine, applies across the microbial world.
If these threats materialize, medicine will need to confront new infectious diseases for which it has no experience. Although the experience with Lyme disease, HIV, SARS coronaviruses, Zika virus, and C. auris shows that medicine and science can eventually respond successfully to previously unknown microbes with new diagnostics, control measures, and therapeutics, effective responses take time, and countless lives are lost in the meantime. However, various measures could be taken today to increase preparedness for confronting new infectious diseases.
Enhance surveillance for new diseases. Designing enhanced surveillance systems for human and animal diseases would provide early information about new pathogenic microbes. Early warning provides potentially actionable information that can be used to design containment measures and diagnostic tests and to develop new therapies and vaccines.
Promote research into nonhuman host-microbe interactions. New pathogenic microbes may use virulence strategies that are fundamentally different from those of known infectious diseases. For example, when HIV burst onto the scene in the 1980s, medical science had no experience with a virus whose pathogenic strategy crippled the immune system and left the host vulnerable to a variety of other lethal infectious diseases. Microbes that are currently pathogenic in plants and invertebrates may pose fundamentally different virulence strategies if they adapt to the human host. Today, medical research needs to be justified concerning its value for human health, and there is often little enthusiasm in diverting scarce research funds into nonhuman diseases. However, it is worth remembering that pioneering work into nonhuman retroviruses in the decades before the HIV epidemic created the knowledge base that allowed rapid progress in developing antiretroviral therapies once HIV was identified as a retrovirus.
Promote continued development of antimicrobial therapeutics. The majority of existing antimicrobial therapeutics target microorganisms associated with humans and livestock. However, these represent an infinitesimally small proportion of the microbial life in the biosphere, and there is no guarantee that currently available antimicrobial therapies would be effective against new pathogenic microbes. This is illustrated with C. auris, which is resistant to several of our most effective antifungal agents. Perhaps the greatest insurance against new organisms would be to develop host-targeted therapies that nonspecifically enhance the ability of hosts to resist infectious diseases.
Develop threat matrices to identify new likely potential threats. Threat matrices are already used to identify the most worrisome pathogenic microbes for biological warfare and bioterrorism (10), which guide research priorities and expenditures on preparedness measures, such as vaccines. Currently, there is probably not enough information available to construct such threat matrices, but any such exercise would inform on the research needed to obtain the required information. With enhanced information into the types of microbial diseases that affect plants and animals and the temperature tolerance of environmental microbes, it should be possible to develop threat matrices that stratify risk of new infectious diseases.
Whereas climate change will almost certainly bring new infectious diseases and change the epidemiology of many existing diseases, it is worthwhile to note with optimism that humanity has confronted new deadly diseases in recent years, such as SARS coronaviruses and Ebola. Previous successes should not be a cause for complacency, and these reflect advances in science and clinical medicine that provide our species with tools to cope with new microbial threats. Clearly, prior success is no guarantee for future success, especially given that each new infectious disease brings in its own set of challenges. The best insurance against future threats is continued investment in surveillance, epidemiology, antimicrobial therapeutics, and basic research into mechanisms of microbial pathogenesis.
Conflict of interest: The author has declared that no conflict of interest exists.
Copyright: © 2020, American Society for Clinical Investigation.
Reference information: J Clin Invest. 2020;130(2):553–555. https://doi.org/10.1172/JCI135003.